☆ 4.4 Editorial Material

MGIP, MGUS, and the PROMISE of meaning in small things

LANCET HAEMATOLOGY (2022)

期刊

LANCET HAEMATOLOGY

卷 9, 期 5, 页码 E315-E317

出版社

ELSEVIER SCI LTD

DOI: 10.1016/S2352-3026(22)00101-6

关键词

-

类别

Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Neurosciences

The promise of small particles: extracellular vesicles as biomarkers in liver pathology

Akshatha N. Srinivas, Diwakar Suresh, Savneet Kaur, Divya P. Kumar

Summary: Extracellular vesicles (EVs) play an important role in the pathophysiology of liver diseases, carrying bioactive cargoes rich in lipids, proteins, and nucleic acids. There is a need for non-invasive and accurate diagnostic tools for early diagnosis and timely treatment of liver diseases, and EVs have emerged as promising candidates for this role.

JOURNAL OF PHYSIOLOGY-LONDON (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?

Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, Christina Li Lin Chai

Summary: This review analyzes the merits and limitations of drugs tested against SARS-CoV-2 and used for adjuvant therapy. Although many of these drugs have been proven ineffective, important lessons can be learned. The recent inclusion of molnupiravir and PaxlovidTM as treatment options for COVID-19 represents our best hope to date for living with COVID-19.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

Outcomes of Patients with Monoclonal Gammopathy of Undetermined Significance with and without Atrial Fibrillation: A Retrospective Cohort Analysis of the Nationwide Inpatient Sample Database

Rachelle Hamadi, Zakaria Alameddine, Samer Asmar, Fouad Sakr, Hussam Aridi, Reem Dimachkie, Hadi Skouri

Summary: This study retrospectively analyzed the data from the Nationwide Inpatient Sample (NIS) in 2018 to investigate the impact of AFIB on MGUS patients. The results showed that MGUS patients with AFIB had higher rates of complications (AKI and pericarditis), longer hospital stays, and higher hospitalization costs. Therefore, screening for AFIB in this patient population is necessary.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy

Justin Chau, Jun Zhang

Summary: The role of the microbiome in immunology is an increasingly important area of study, with research showing links between the microbiome and tumorigenesis, chemotherapy and radiation potentiation, as well as immune checkpoint inhibitor efficacy and immune-related adverse events.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Small Molecule Inhibitors of White Spot Syndrome Virus: Promise in Shrimp Seedling Culture

Lei Liu, Li-Peng Shan, Yan Zhou, Jiong Chen

Summary: The synthesis of coumarin derivatives C2 and C7 has shown promising antiviral effects against white spot syndrome virus in Litopenaeus vannamei larvae, reducing toxicity and mortality while remaining stable in aquacultural water. These compounds have the potential for use in prevention and treatment of WSSV infection in shrimp seedling culture.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Hematology

Investigation and management of the monoclonal gammopathy of undetermined significance A British Society for Haematology Good Practice Paper

Simon Stern, Satarupa Chaudhuri, Mark Drayson, Sarah Henshaw, Kamaraj Karunanithi, Fenella Willis

Summary: This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of MGUS. It also discusses the entity of MGCS and how it should be managed. Additionally, the potential for targeted population screening for MGUS is explored.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma

Normann Steiner, Georg Goebel, Daniela Michaeler, Anna-Luise Platz, Wolfgang Prokop, Anna Maria Wolf, Dominik Wolf, Christina Duftner, Eberhard Gunsilius

Summary: Chronic inflammatory diseases, especially non-antibody-mediated diseases, double the risk of progression from MGUS to overt multiple myeloma. Comorbidities like rheumatic diseases may need to be considered in MGUS prognostic scores.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Nutrition & Dietetics

Nutritional Status Indices and Monoclonal Gammopathy of Undetermined Significance Risk in the Elderly Population: Findings from the National Health and Nutrition Examination Survey

Linfeng Li, Mengrui Wu, Zhengyu Yu, Ting Niu

Summary: This study found that older adults with poorer nutritional status have a higher risk of MGUS.

NUTRIENTS (2023)

添加到收藏夹

Article Hematology

A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis

Sriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, Sajitha Sachchithanantham, Rakesh Popat, Helen Lachmann, Neil Rabin, Karthik Ramasamy, Stephen Hawkins, Charalampia Kyriakou, Julian Gillmore, Kwee Yong, Philip Hawkins, Graham Jackson, Guy Pratt, Ashutosh D. Wechalekar

Summary: This study found that depth of response is critical in the prognosis of AL amyloidosis. By analyzing patients' baseline characteristics and 1-month response, those unlikely to improve treatment response can be identified. It is recommended that patients with a significant difference in involved and uninvolved serum free light chains at diagnosis and no response at 1 month switch treatment early.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Hematology

The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?

Hannah Giles, Ashutosh Wechalekar, Guy Pratt

Summary: Mass spectrometry techniques offer a highly sensitive method for evaluating and monitoring paraproteins compared to standard electrophoretic techniques, providing valuable insights for clinical assessment and clinical trial enrollment. The increased sensitivity of these assays helps detect and monitor monoclonal proteins more effectively and can increase detection rates of low-level monoclonal proteins.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

The promise of precision medicine in rheumatology

Joel M. Guthridge, Catriona A. Wagner, Judith A. James

Summary: Precision medicine for rheumatic diseases is still in its early stages, but recent advancements have allowed for comprehensive profiling and mechanistic insights. The individualization of treatment based on underlying pathogenic mechanisms is the ultimate goal in caring for systemic autoimmune rheumatic diseases (SARDs). While current strategies such as treat-to-target therapies and autoantibody testing are not optimal, innovations in high-throughput 'omic' technologies have the potential to improve outcomes and identify new treatment pathways. However, there are numerous challenges in translating these findings into clinical practice.

NATURE MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis

Makiko Nakamura, Teruhiko Imamura, Ryuichi Ushijima, Koichiro Kinugawa

Summary: Recent clinical trials have shown that Tafamidis can reduce the all-cause mortality and cardiovascular hospitalizations in patients with transthyretin cardiac amyloidosis. However, the optimal surrogate markers during Tafamidis treatment are still unknown.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Artificial intelligence in small bowel capsule endoscopy - current status, challenges and future promise

Xavier Dray, Dimitris Iakovidis, Charles Houdeville, Rodrigo Jover, Dimitris Diamantis, Aymeric Histace, Anastasios Koulaouzidis

Summary: Neural network-based solutions are being developed to aid physicians in reviewing small-bowel capsule endoscopy, with computer-assisted detection being a critical step. While weakly supervised solutions have shown promising results, more video-level evaluations and prospective studies are needed in the future.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Review Oncology

Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment

Sabine Karam, Mohammad Haidous, Iman Abou Dalle, Amelie Dendooven, Nour Moukalled, Amaryllis Van Craenenbroeck, Ali Bazarbachi, Ben Sprangers

Summary: Monoclonal gammopathy of renal significance (MGRS) refers to a group of kidney disorders caused by a monoclonal immunoglobulin (MIg) that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can lead to end stage kidney disease (ESKD). Diagnosis is made through kidney biopsy and treatment should be coordinated between hematologists and nephrologists based on the type of MGRS, degree of kidney function impairment, and risk of progression to ESKD.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

添加到收藏夹

Article Psychology, Multidisciplinary

The Role and Meaning of the Digital Transformation As a Disruptive Innovation on Small and Medium Manufacturing Enterprises

Vasja Roblek, Maja Mesko, Franci Pusavec, Borut Likar

Summary: This paper explores the impact of digital transformation as a disruptive innovation on manufacturing SMEs through a qualitative Delphi study involving 49 experts from eleven EU countries. It aims to show how disruptive innovations affect organizational changes and determine critical factors impacting R&D, discovering impacts on product/process development methods, new materials, and organization plans. The analysis reveals three main groups of disruptive innovations and their influence on smart factory development in the future.

FRONTIERS IN PSYCHOLOGY (2021)

添加到收藏夹

Article Oncology

Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis

Omer H. Jamy, Aditi Dhir, Luciano J. Costa, Ana C. Xavier

Summary: The study found that there have been consistent improvements in early mortality (EM) and overall survival (OS) for patients with APL over the past 20 years. However, challenges remain in extending these improvements to older patients and those living in rural areas.

CANCER (2022)

添加到收藏夹

Letter Hematology

Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma

Smith Giri, Susan Bal, Kelly N. Godby, Gayathri Ravi, Deanna Clark, Clare Ubersax, Abigail Cooley, Priscila White, Sunil Rangarajan, Grant R. Williams, Luciano J. Costa

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Revisiting the impact of immunoglobulin isotypes in multiple myeloma

Susan Bal, Smith Giri, Kelly N. Godby, Luciano J. Costa

Summary: The association of IgA and light chain isotypes with poorer overall survival in multiple myeloma patients suggests their unique biology beyond the presence of adverse prognostic factors.

ANNALS OF HEMATOLOGY (2022)

添加到收藏夹

Letter Biophysics

Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients

Christianne Toledo de Souza Leal, Luciano Jose Megale Costa, Juliana Pereira, Fernando Barroso Duarte, Raphael Barros Tavares, Angelo Atalla, Bruna Sousa Sabioni, Abrahao Elias Hallack Neto

BONE MARROW TRANSPLANTATION (2022)

添加到收藏夹

Article Oncology

Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable

A. K. Nooka, L. J. Costa, C. J. Gasparetto, P. G. Richardson, D. S. Siegel, A. Chari, S. Lentzsch, S. Jagannath, J. Mikhael

Summary: Selinexor is a selective inhibitor of nuclear export that blocks the protein transporter XPO1, leading to nuclear preservation and activation of tumor suppressor proteins and prevention of mRNA translation of oncoproteins. The combination of Selinexor with dexamethasone has shown therapeutic value in treating refractory myeloma and has received FDA approval. This article summarizes the supportive care solutions for weekly dosing of Selinexor.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Oncology

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

Luciano J. Costa, Yi Lin, R. Frank Cornell, Thomas Martin, Saurabh Chhabra, Saad Z. Usmani, Sundar Jagannath, Natalie S. Callander, Jesus G. Berdeja, Yubin Kang, Ravi Vij, Kelly N. Godby, Ehsan Malek, Amarendra Neppalli, Michaela Liedtke, Mark Fiala, Hong Tian, Satish Valluri, Jennifer Marino, Carolyn C. Jackson, Arnob Banerjee, Ankit Kansagra, Jordan M. Schecter, Shaji Kumar, Parameswaran Hari

Summary: This study compared the efficacy of cilta-cel with real-world therapies in patients with relapsed/refractory multiple myeloma. The results showed that cilta-cel had significantly higher overall response rate, longer progression-free survival, and overall survival compared to standard-of-care therapies.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Oncology

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander

Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Hematology

Bispecific T-cell engagers for treatment of multiple myeloma

Gayathri Ravi, Luciano J. Costa

Summary: Bispecific T cell engagers (TCE) are a promising therapy for multiple myeloma, as they activate T cells and induce lysis of tumor cells by binding to specific proteins on their surfaces. Current development focuses on targeting different proteins and improving their structure and administration. TCEs have shown positive responses in phase 1 trials, with potential toxicities being cytokine release syndrome and cytopenias.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

Douglas W. Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A. Efebera, Cesar Rodriguez, Luciano J. Costa, Ajai Chari, Rebecca Silbermann, Sarah A. Holstein, Larry D. Anderson, Jonathan L. Kaufman, Nina Shah, Huiling Pei, Sharmila Patel, Annelore Cortoos, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson

Summary: Patients with multiple myeloma have an increased risk of vascular thromboembolic events (VTEs). Adding daratumumab to the RVd treatment did not increase the incidence of VTEs, but the cumulative incidence of VTEs was relatively high in this cohort and the use of anti-thrombotic prophylaxis was suboptimal.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Oncology

Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy

Susan Bal, Timothy M. Schmidt, Luciano J. Costa, Natalie S. Callander

Summary: Multiple myeloma is a complex hematological malignancy with heterogeneity in clinical manifestations, biological processes, and patient outcomes. Although traditional biomarkers have limited predictive value, detection of measurable residual disease (MRD) has emerged as an essential tool in evaluating patients with myeloma.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Letter Hematology

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study

Binod Dhakal, Mei-Jei Zhang, Linda J. Burns, Xiaoying Tang, Christa Meyer, Lih-Wen Mau, Ajay K. Nooka, Edward Stadtmauer, Ivana N. Micallef, Joseph McGuirk, Luciano Costa, Mark B. Juckett, Nina Shah, Richard E. Champlin, Saad Z. Usmani, Sherif S. Farag, Taiga Nishihori, Vivek Roy, Andrew Bodiford, Yvonne J. Barnes, Edward J. Drea, Parameswaran Hari, Mehdi Hamadan

HAEMATOLOGICA (2023)

添加到收藏夹

Article Medicine, General & Internal

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody

Ajai Chari, Monique C. Minnema, Jesus G. Berdeja, Albert Oriol, Niels W. C. J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Raluca Verona, Suzette Girgis, Shiyi Yang, Rachel B. Goldsmith, Xiang Yao, Kodandaram Pillarisetti, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Amrita Krishnan

Summary: Talquetamab treatment exhibited common adverse events like cytokine release syndrome, skin-related events, and dysgeusia, which were primarily low-grade; however, the drug induced substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Letter Oncology

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Gregory S. Calip, Mustafa S. Ascha, Xiaoliang Wang, Samuel M. Rubinstein, Sascha Tuchman, Luciano Costa, Benjamin Haaland, Smith Giri, Hira Mian, Rafael Fonseca, Douglas Sborov

BLOOD CANCER JOURNAL (2022)

添加到收藏夹

Article Hematology

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

Saurabh Chhabra, Natalie Callander, Nicole L. Watts, Luciano J. Costa, Bicky Thapa, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Larry D. Anderson, Susan Bal, Binod Dhakal, Nitya Nathwani, Nina Shah, Eva Medvedova, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Timothy Schmidt, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, R. Frank Cornell, James H. Jerkins, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees

Summary: For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care includes induction therapy followed by autologous stem cell transplantation (ASCT). Daratumumab as monotherapy and in combination treatment is approved across multiple lines of therapy for multiple myeloma (MM), and lenalidomide is an effective and commonly used agent for induction and maintenance therapy in MM. However, there is concern that lenalidomide and daratumumab given as induction therapy might impair mobilization of stem cells for ASCT.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

添加到收藏夹

Article Hematology

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Binod Dhakal, Nina Shah, Ankit Kansagra, Ambuj Kumar, Sagar Lonial, Alfred Garfall, Andrew Cowan, Bishesh Sharma Poudyal, Caitlin Costello, Francesca Gay, Gordon Cook, Hang Quach, Herman Einsele, Jeff Schriber, Jian Hou, Luciano Costa, Mahmoud Aljurf, Maria Chaudhry, Meral Beksac, Miles Prince, Mohamad Mohty, Murali Janakiram, Natalie Callander, Noa Biran, Pankaj Malhotra, Paula Rodriguez Otero, Philippe Moreau, Rafat Abonour, Raheel Iftikhar, Rebecca Silberman, Sham Mailankody, Tara Gregory, Yi Lin, Paul Carpenter, Mehdi Hamadani, Saad Usmani, Shaji Kumar

Summary: Therapeutic options in multiple myeloma have changed dramatically in the past decade. A panel of experts formulated clinical practice recommendations for the role, timing, and sequencing of autologous and allogeneic hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy. The panel endorsed the use of auto-HCT consolidation for newly diagnosed patients and recommended its use in the first relapse for patients not undergoing upfront auto-HCT.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.